Still, injectables are more reliable
However, intranasal administration is also considered an efficient route for systemic effects due to the dense vasculature of the nasal mucosa
sometimes used off-label for weight loss) These medicationsall available as injectables, tablets, or oral dropsare accessible today through a clinician and may be a strong option for people who dont qualify for or dont want to wait to get retatrutide with a clinical trial
First, phase II clinical trials evaluating MOTS-c in type 2 diabetes and sarcopenia are in development, and their results will provide the first randomized controlled evidence in humans to define therapeutic doses with statistical rigor
For laboratory handling context on the copper-peptide component specifically, see our GHK-Cu handling guide
Cagrilintide monotherapy has the lowest treatment discontinuation rate of any major weight loss peptide in clinical trials